Jianyuan Tang

Dr. Jianyuan Tang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
ZWZhilei Wang
Zhilei Wang
YLYuchen Li
Yuchen Li
WLWenhao Liao
Wenhao Liao
JHJu Huang
Ju Huang
YLYanping Liu
Yanping Liu
JTJianyuan Tang
Jianyuan Tang
The incidence of hyperuricemia (HUA) and gout continuously increases and has become a major public health problem. The gut microbiota, which colonizes the human intestine, has a mutually beneficial and symbiotic relationship with the host and plays a vital role in the host’s metabolism and immune regulation. Structural changes or imbalance in the gut microbiota could cause metabolic disorders and participate in the synthesis of purine-metabolizing enzymes and the release of inflammatory cytokines, which is closely related to the occurrence and development of the metabolic immune disease HUA and gout. The gut microbiota as an entry point to explore the pathogenesis of HUA and gout has become a new research hotspot. This review summarizes the characteristics of the gut microbiota in patients with HUA and gout. Meanwhile, the influence of different dietary structures on the gut microbiota, the effect of the gut microbiota on purine and uric acid metabolism, and the internal relationship between the gut microbiota and metabolic endotoxemia/inflammatory factors are explored. Moreover, the intervention effects of probiotics, prebiotics, and fecal microbial transplantation on HUA and gout are also systematically reviewed to provide a gut flora solution for the prevention and treatment of related diseases.

28 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HZHong Zhang
Hong Zhang
CYCheng-Hao Yu
Cheng-Hao Yu
YJYi-Ping Jiang
Yi-Ping Jiang
CPCheng Peng
Cheng Peng
KHKun He
Kun He
XHXin Hailiang
Xin Hailiang
Polydatin is one of main compounds in Polygonum cuspidatum, a plant with both medicinal and nutritional value. The possible hepatoprotective effects of polydatin on acute liver injury mice induced by carbon tetrachloride (CCl4) and the mechanisms involved were investigated. Intraperitoneal injection of CCl4 (50 µl/kg) resulted in a significant increase in the levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and hepatic malondialdehyde (MDA), also a marked enhancement in the expression of hepatic tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and nuclearfactor-kappa B (NF-κB). On the other hand, decreased glutathione (GSH) content and activities of glutathione transferase (GST), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) were observed following CCl4 exposure. Nevertheless, all of these phenotypes were evidently reversed by preadministration of polydatin for 5 continuous days. The mRNA and protein expression levels of hepatic growth factor-beta1 (TGF-β1) were enhanced further by polydatin. These results suggest that polydatin protects mice against CCl4-induced liver injury through antioxidant stress and antiinflammatory effects. Polydatin may be an effective hepatoprotective agent and a promising candidate for the treatment of oxidative stress- and inflammation-related diseases.

22 May 2020 in Journal of Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
XMXitao Ma
Xitao Ma
YWYanqiao Wang
Yanqiao Wang
TGTian Gao
Tian Gao
QHQing He
Qing He
YHYan He
Yan He
JTJianyuan Tang
Jianyuan Tang
The number of research involving human subjects on coronavirus disease 2019 (COVID‐19) is surging, bringing challenges to the ethical review committee (ERC) in terms of reviewing speed and special ethical considerations under the pandemic. However, the existing ethical review system and regulations have their limitations to meet the demand for a prompt and efficient epidemic control. Since the research under the public health emergency is different from that carried out in familiar situations to design and implementation, the strategy for a satisfactory ERC response should balance the duty of protecting individual participants as well as the special public needs derived from the disease control. It is suggested that the ethical review‐related regulations need to be updated, and a unified supervision system to the overall ERC is required. ERC collaboration, capacity‐improving and efficiency‐improving measures need to be taken. With respect to the reviewing guidelines, it is suggested that the international norms should be explained with more consideration of the local condition and the exceptional circumstances in this public health emergency. A joint effort needs to be taken for better research conduction.

1 June 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HLHai-Yue Lan
Hai-Yue Lan
PAPei An
Pei An
QLQiu-Ping Liu
Qiu-Ping Liu
YCYu-Ying Chen
Yu-Ying Chen
YYYuan-Yuan Yu
Yuan-Yuan Yu
HZHong Zhang
Hong Zhang

18 August 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
LYLuyao Yang
Luyao Yang
HCHongqing Chen
Hongqing Chen
QHQiongying Hu
Qiongying Hu
LLLu Liu
Lu Liu
YYYun Yuan
Yun Yuan
XSXiaofei Shen
Xiaofei Shen

1 November 2022 in Pharmacological Research
Verified
Journal Article
Closed access
LQLiping Qu
Liping Qu
XLXiuli Li
Xiuli Li
YXYin Xiong
Yin Xiong
ZWZhun Wang
Zhun Wang
YZYuehua Zhou
Yuehua Zhou
MWMei Wang
Mei Wang